

Detail of Pharmaceutical Funding Sources (01.01.2024 – 31.12.2024)

Income indicated below relates to: Congress Exhibition, Programme Advertisements, Sponsored Symposia, and General Onsite Sponsoring; Society initiatives sponsoring

Industry-related Income in 2024: Breakdown

Contributing companies in 2024	Total contribution in 2024	% of Total income in 2024
Al:ON Innovations, Inc.	€ 2'500.00	0.03%
Alexion, AstraZeneca Rare Disease	€ 378'600.00	5.12%
Amgen	€ 248'200.00	3.36%
Bristol Myers Squibb	€ 419'800.00	5.68%
BioCure	€ 3'210.00	0.04%
BIOSYNEX Theradiag	€ 3'210.00	0.04%
Chugai Pharmaceutical Co., Ltd.	€ 80'000.00	1.08%
Fujirebio Europe	€ 6'420.00	0.09%
Icometrix	€ 3'210.00	0.04%
Immunis AG	€ 9'630.00	0.13%
JuneBrain Inc.	€ 2'500.00	0.03%
Juvisé Pharmaceuticals	€ 47'860.00	0.65%
Kyverna Therapeutics	€ 96'830.00	1.31%
machineMD AG	€ 2'500.00	0.03%
MotoMed	€ 3'210.00	0.04%
Merck Healthcare KGaA	€ 478'500.00	6.47%
Novartis Pharma AG	€ 319'240.00	4.32%
Octave Bio	€ 30'130.00	0.41%
Ottobock	€ 22'920.00	0.31%
Parexel International	€ 19'710.00	0.27%
Quanterix	€ 11'920.00	0.16%
Roche	€ 421'950.00	5.71%
Sandoz	€ 122'800.00	1.66%
Sanofi	€ 665'700.00	9.00%
Sysnav Healthcare	€ 3'210.00	0.04%
TG Therapeutics & Neuraxpharm	€ 204'200.00	2.76%
UCB	€ 50'275.00	0.68%
ViewMind	€ 4'815.00	0.07%
Wieslab Diagnostic Service	€ 3'210.00	0.04%
Total Industry Income in 2024	€ 3'666'260.00	